Octanate: Main Uses and Benefits

Octanate is a treatment option used for individuals diagnosed with Haemophilia A. This condition, resulting from a congenital factor VIII deficiency, is associated with prolonged or spontaneous bleeding episodes.

Quick Facts

• Primary Use: Management of bleeding episodes in Haemophilia A.
• Secondary Use: Prophylaxis (prevention) of bleeding in severe Haemophilia A.
• Additional Use: Perioperative management to support haemostasis during surgical procedures.

The medication's main function is to temporarily replace the missing factor VIII in the blood, which is necessary for effective blood clotting. Its use is focused on two key therapeutic domains:

1. On-Demand Management of Bleeding: It may be administered to control and resolve acute bleeding episodes, such as those occurring in joints (haemarthrosis), muscles, or following trauma. This approach helps to stabilize the patient's condition.
2. Long-Term Bleeding Prophylaxis: For patients with severe Haemophilia A, regular use may help to prevent or reduce the frequency of bleeding occurrences, contributing to reduced long-term joint damage and potential morbidity. The patient's physician determines the appropriate treatment regimen based on individual need.

Who Can and Cannot Use Octanate?

This section defines the official population eligibility and non-eligibility requirements for Octanate based on regulatory documents, strictly addressing who can and cannot receive the medication.

---

Eligibility Scope

Classification	Population or Condition
Indicated Use	Patients with Haemophilia A (congenital factor VIII deficiency) for treatment and prophylaxis of bleeding.
Age Eligibility	Indicated for all age groups, covering both the paediatric population (children and adolescents) and adults.
Contraindicated	Patients with known hypersensitivity (allergy) to the active substance (human coagulation factor VIII) or to any of the product’s inactive components.
Use Not Indicated	The medicine is explicitly not indicated for patients diagnosed with von Willebrand disease.

---

Special Population Considerations

• Pregnancy and Lactation: Official guidance notes that the safety profile has not been definitively established. Eligibility is determined by a physician based on the necessity of treating the underlying Haemophilia A.
• Factor VIII Inhibitors: Use is conditionally restricted for patients who develop Factor VIII inhibitors, as the treatment may become ineffective and requires specialist medical management.

---

The regulatory profile establishes eligibility based on the Haemophilia A diagnosis and prohibits use only due to a hypersensitivity reaction. All other populations are permitted use under the primary indication, with specific caution needed regarding the development of Factor VIII inhibitors.

Interactions with other medicines and products

Regulatory documentation for human coagulation factor VIII products, such as Octanate, indicates a highly specific interaction profile. The most significant information is the absence of known systemic interactions with other medicinal products, supplements, or substances.

Factor VIII is a large human protein and is not metabolized by the Cytochrome P450 (CYP) enzyme system, which is typically responsible for drug-drug interactions involving many oral medications. Consequently, official prescribing information states that Octanate is not known to interact with other medicines, meaning that formal classifications of pharmacokinetic (PK) or pharmacodynamic (PD) interactions are not documented in government sources.

---

Administration-Related Restriction

The single explicit constraint noted in the product labeling relates to its administration. This restriction is based on the risk of physico-chemical incompatibility, which can cause the product to degrade and lose efficacy. Therefore, Octanate must not be mixed with any other medicinal product in the same solution for injection or infusion. Administration must be separate from all other substances.

Interaction Type	Official Regulatory Statement
Systemic Drug-Drug Interactions	None known. No documented PK/PD interactions.
Food, Alcohol, Supplements	None documented.
Co-Mixing Restriction	Must not be mixed with any other medicinal product during administration.

Mechanism of Cofactor Replacement and Cascade Restoration

The drug's primary mechanism involves the direct replacement of the deficient Factor VIII (FVIII) protein. FVIII functions as an essential cofactor that binds to Factor IXa, forming the Tenase complex on activated cell surfaces. This crucial step is the rate-limiting reaction in the intrinsic coagulation pathway; by restoring FVIII, the drug exponentially accelerates the conversion of Factor X to Factor Xa. This rapid, targeted action facilitates the generation of a high volume of thrombin and leads to the assembly of a stable fibrin clot, thereby correcting the underlying defect in the intrinsic pathway.

---

️ Functional Stability Provided by Von Willebrand Factor

Octanate contains FVIII non-covalently bound to von Willebrand factor (VWF), which acts as a protective carrier protein. Mechanistically, VWF shields the administered FVIII from premature degradation by plasma proteases. This protective action is a key mechanistic domain that sustains the functional concentration of FVIII in the plasma, maintaining a prolonged duration of the cofactor replacement activity.

---

Constraints Imposed by Inhibitory Alloantibodies

A key limitation of the mechanism is its vulnerability to inhibitory alloantibodies (inhibitors). These antibodies specifically neutralize the FVIII protein, blocking its ability to bind to Factor IXa and form the Tenase complex. This antagonistic biological reaction overrides the replacement mechanism, resulting in the functional neutralization of FVIII's ability to activate Factor X, which severely constraints FVIII's participation in the Tenase complex.

Octanate is a specialized Factor VIII concentrate that is exclusively administered by intravenous (IV) injection or slow infusion after reconstitution. The dosing is highly individualized and strictly guided by the principles of substitution therapy, where the goal is to raise the patient's plasma Factor VIII activity to a targeted percentage for effective coagulation.

---

Dosing Calculation and Schedules

Dose Calculation

The required dose in International Units (IU) is calculated based on the empirical principle that 1 IU of Factor VIII per kilogram of body weight raises the plasma FVIII activity by approximately 2% of normal activity. The dose is calculated using the following formula:

Dose (IU) = Body Weight (kg) imes Desired FVIII Increase (%) imes 0.5

Usage Patterns

Regimen	Dose Range (IU/kg)	Frequency/Duration Pattern
On-Demand Treatment	Calculated to achieve 20-100% FVIII activity.	Typically repeated every 8 to 24 hours until the bleeding is resolved, based on event severity.
Prophylaxis	20 to 40 IU/kg	Scheduled administration, commonly two to three times per week for long-term prevention.

---

Administration Instructions

Octanate is supplied as a lyophilised powder and must be reconstituted with the provided solvent immediately before use. The solution should be gently swirled, not shaken, until fully dissolved. The final product must be clear or slightly opalescent and used within a short, specified timeframe, such as three hours, to maintain potency and integrity. The solution is then injected slowly into a vein; the maximum infusion rate is typically constrained to 2-3 mL per minute. The dosage and frequency for all regimens, particularly during major procedures, must be monitored and adjusted according to measured FVIII plasma levels.

Research Evidence / Overview of Studies

Key Findings from Clinical Research

Research has examined this drug as an analgesic and anti-inflammatory agent. Studies have examined changes in patient comfort and pain levels following surgery. Research has evaluated the occurrence of adverse events during short-term use in studied populations.

Studies evaluated changes in inflammation markers following specific dosing schedules used in trials. A key finding from some studies was an association with a change in patient-reported pain duration.

---

Study Design and Population

Initial Phase I trials primarily examined the pharmacokinetics and maximum tolerated dose in healthy adult volunteers.

Phase II trials were non-blinded and primarily focused on dose-ranging. Studies explored the inclusion of patients reporting mild to moderate musculoskeletal pain. These studies examined safety markers, with a focus on hepatic and renal function.

Phase III trials included randomized, double-blind, placebo-controlled designs. Studies compared the analgesic response against placebo or other agents. The populations examined included individuals with:

• Acute post-operative pain
• Chronic low back pain
• Osteoarthritis of the knee

---

Safety and Tolerability Profile

Research has explored cardiovascular event rates in study participants with pre-existing heart conditions. Studies have examined the change in the frequency of reported gastrointestinal events with co-administration of food.

Clinical studies have examined data related to the targeted inflammatory pathway. Studies explored time to reported change and changes in reported pain levels during acute pain flares. The overall rate of adverse events was evaluated by researchers by tracking reporting across all study phases.

Key Studies & References

1. Post-op pain and blood loss in total knee arthroplasty- an rct using periarticular injection with diclofenac-based multimodal drugs - JMAT
2. American College of Physicians issues guideline for treating nonradicular low back pain | ACP Online

Common questions about Octanate (FAQ)

Q: How is Octanate different from other Factor VIII treatments?

According to official product information, Octanate is classified as a plasma-derived Factor VIII concentrate because its active ingredient is sourced from screened and pooled human plasma. This distinguishes it from recombinant Factor VIII products, which are manufactured using non-human cell lines. This difference in source is the primary characteristic that sets it apart from other types of Factor VIII treatments.

Q: What does the term 'prophylaxis' mean in the context of Octanate use?

Prophylaxis is a scheduled treatment regimen used for the long-term prevention of bleeding episodes. This approach involves the regular, scheduled administration of Octanate, which typically involves administration two to three times per week, as defined in the regimen. The intent of this approach is to help avoid spontaneous bleeding, rather than waiting to treat an active bleed.

Q: Is Octanate approved for conditions other than Hemophilia A?

Official documents state that Octanate is indicated for patients with Haemophilia A, which is a congenital factor VIII deficiency. The product is specifically not indicated for use in patients with von Willebrand disease. Its use is strictly defined by the need to replenish the missing Factor VIII protein in Haemophilia A.

Q: What are the common reasons a healthcare provider might stop Octanate treatment?

A healthcare provider may need to stop Octanate treatment if a patient develops a known hypersensitivity (an allergy) to the product. Treatment may also be restricted if the patient develops Factor VIII inhibitors, which are neutralizing antibodies that can make the medicine ineffective. Decisions regarding discontinuation or switching products are highly specific and managed by the patient's medical team.

Q: What does the term "on-demand" use mean for Octanate?

On-demand treatment is a regimen used specifically when a patient experiences an active bleeding episode or event. This approach provides the Factor VIII concentrate necessary to help the blood clot and resolve the immediate bleeding. The dose pattern is typically designed to be repeated until the bleeding is medically controlled.

Q: Is the use of Octanate considered a cure for Hemophilia A?

No, the official documents do not describe the use of Octanate as a cure for Haemophilia A. Its purpose is defined as substitution therapy, which means it provides a temporary replacement of the deficient Factor VIII protein. This action offers a critical, temporary correction of the factor deficiency to support blood clotting.

Q: Can Octanate be stored at room temperature for a short period before mixing?

The unopened powder and solvent vials must be stored in a refrigerator, but the product is generally allowed to reach room temperature before reconstitution. Official product information states that the unopened product may be stored up to 25^\circC and must not be frozen. The official guidance indicates that to maintain potency and integrity, the solution is intended for prompt use after reconstitution.

Q: What is the meaning of the classification given to Octanate?

Octanate is officially classified as a Human Coagulation Factor VIII Concentrate. This classification places it within the larger pharmacological category of Antihemorrhagics (clotting factors). This designation defines its medical use as replacing the essential Factor VIII protein required for normal blood coagulation.

Q: What are the typical long-term effects described for patients using Octanate?

The primary long-term effect described in official safety documents is the risk of Factor VIII inhibitor formation. Inhibitors are antibodies that may develop in the body, which can neutralize the medication and reduce its effectiveness over time. This risk is documented as continuing throughout a patient's life.

Q: Are changes in blood pressure or heart rate a recognized side effect of Octanate?

While changes in blood pressure are not listed as a common adverse reaction, official administration instructions mention that patients should be monitored for changes in heart rate. If a marked increase in pulse rate occurs during the infusion, the regulatory documents outline a protocol where the injection speed is reduced or administration is interrupted.

Q: What general warnings are given about using Octanate while driving or operating machinery?

According to regulatory documents, no effects on the ability to drive and use machines have been observed following the use of Octanate. This statement addresses the general safety profile regarding these activities.

Q: What should be done if small particles are observed in the Octanate vial before preparation?

The prepared solution is expected to be clear or slightly opalescent after reconstitution. Official guidance requires the product to be inspected visually for particulate matter or discoloration before use. If particulate matter is observed in the vial, regulatory standards require that the product must not be used and should be handled as pharmaceutical waste.

Q: Are there any religious or cultural concerns related to the sourcing of Octanate?

Octanate is sourced from pooled human plasma. Regulatory documents define the rigorous processes used to ensure the safety and purity of the product, including steps for virus inactivation and screening. This framework is intended to mitigate the risks associated with its human origin.

How to Store and Dispose of Octanate

The storage and handling of Octanate (Human Coagulation Factor VIII) must strictly follow the conditions defined in official regulatory labeling.

---

Required Storage Conditions

• Temperature: The unopened powder and solvent vials must be stored in a refrigerator at a temperature between 2 C and 8 C.
• Protection: The product must be kept in the original outer carton to protect the vials from light.
• Handling: The vials must not be frozen. Before reconstitution, the powder and solvent should be allowed to reach room temperature.
• Child Safety: Keep the medicinal product out of the sight and reach of children.

Stability and Disposal

• The reconstituted solution is for single use only and must be used immediately after preparation to prevent contamination.
• Do not use the product after the expiration date on the label.
• Any unused medicinal product or waste material, including empty vials and components, must be disposed of in accordance with local requirements for pharmaceutical waste.